EP1390410A4 - Molecules for disease detection and treatment - Google Patents

Molecules for disease detection and treatment

Info

Publication number
EP1390410A4
EP1390410A4 EP02739428A EP02739428A EP1390410A4 EP 1390410 A4 EP1390410 A4 EP 1390410A4 EP 02739428 A EP02739428 A EP 02739428A EP 02739428 A EP02739428 A EP 02739428A EP 1390410 A4 EP1390410 A4 EP 1390410A4
Authority
EP
European Patent Office
Prior art keywords
molecules
treatment
disease detection
disease
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739428A
Other languages
German (de)
French (fr)
Other versions
EP1390410A1 (en
Inventor
Tom Y Tang
Henry Yue
Mariah R Baughn
Brendan M Duggan
Bridget A Warren
Olga Bandman
Thomas W Richardson
Neil Burford
Bharati Sanjanwala
Shanya D Becha
Monique G Yao
Junming Yang
Uyen K Tran
April J A Hafalia
Jennifer A Griffin
Anita Swarnakar
Vicki S Elliott
Shirley A Recipon
Farrah A Khan
Ernestine A Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of EP1390410A1 publication Critical patent/EP1390410A1/en
Publication of EP1390410A4 publication Critical patent/EP1390410A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
EP02739428A 2001-05-25 2002-05-24 Molecules for disease detection and treatment Withdrawn EP1390410A4 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US29372301P 2001-05-25 2001-05-25
US293723P 2001-05-25
US29525701P 2001-06-01 2001-06-01
US295257P 2001-06-01
US29722001P 2001-06-08 2001-06-08
US297220P 2001-06-08
US30052601P 2001-06-21 2001-06-21
US300526P 2001-06-21
US30187401P 2001-06-29 2001-06-29
US301874P 2001-06-29
US35941302P 2002-02-22 2002-02-22
US359413P 2002-02-22
PCT/US2002/016676 WO2002096951A1 (en) 2001-05-25 2002-05-24 Molecules for disease detection and treatment

Publications (2)

Publication Number Publication Date
EP1390410A1 EP1390410A1 (en) 2004-02-25
EP1390410A4 true EP1390410A4 (en) 2006-01-11

Family

ID=27559619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739428A Withdrawn EP1390410A4 (en) 2001-05-25 2002-05-24 Molecules for disease detection and treatment

Country Status (4)

Country Link
EP (1) EP1390410A4 (en)
JP (1) JP2005508142A (en)
CA (1) CA2448116A1 (en)
WO (1) WO2002096951A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092009A1 (en) 2000-11-16 2003-05-15 Kaia Palm Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US20090226929A1 (en) * 2006-03-16 2009-09-10 Hydra Biosciences, Inc Titinic ion channel, compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075298A2 (en) * 1999-06-03 2000-12-14 Incyte Genomics, Inc. Molecules for disease detection and treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075298A2 (en) * 1999-06-03 2000-12-14 Incyte Genomics, Inc. Molecules for disease detection and treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 1 October 2000 (2000-10-01), "Interleukin-6 precursor (IL-6) (B-cell stimulatory factor 2) (BSF-2) (Interferon beta-2) (Hybridoma growth factor) (CTL differentiation factor) (CDF)", XP002308417, Database accession no. P05231 *
PAPANICOLAOU D A ET AL: "The pathophysiologic roles of interleukin-6 in human disease.", ANNALS OF INTERNAL MEDICINE. 15 JAN 1998, vol. 128, no. 2, 15 January 1998 (1998-01-15), pages 127 - 137, XP002308416, ISSN: 0003-4819, Retrieved from the Internet <URL:http://www.annals.org/cgi/content/full/128/2/127> [retrieved on 20041201] *
SAVINO R ET AL: "GENERATION OF INTERLEUKIN-6 RECPETOR ANTAGONISTS BY MOLECULAR-MODELING GUIDED MUTAGENESIS OF RESIDUES IMPORTANT FOR GP130 ACTIVATION", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 6, 15 March 1994 (1994-03-15), pages 1357 - 1367, XP000565719, ISSN: 0261-4189 *
See also references of WO02096951A1 *
YASUKAWA K ET AL: "STRUCTURE AND EXPRESSION OF HUMAN B CELL STIMULATORY FACTOR-2 (BSF-2/IL-6) GENE", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 6, no. 10, 1987, pages 2939 - 2945, XP002950930, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
JP2005508142A (en) 2005-03-31
EP1390410A1 (en) 2004-02-25
WO2002096951A1 (en) 2002-12-05
CA2448116A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
AU2002338265A1 (en) Molecules for disease detection and treatment
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HK1043625A1 (en) Kidney disease detection and treatment
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2002329784A1 (en) Molecules for disease detection and treatment
AU2002318356A8 (en) Protein modification and maintenance molecules
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
AU2002364890A8 (en) Molecules for disease detection and treatment
AU2001241709A1 (en) Molecules for disease detection and treatment
AU2002243539A1 (en) Molecules for disease detection and treatment
AU2002347899A1 (en) Molecules for disease detection and treatment
AU2003205174A1 (en) Molecules for disease detection and treatment
AU2002327945A1 (en) Human delta-n p73 molecules and uses thereof
GB0115780D0 (en) Therapeutic molecules and uses thereof
AU2002359567A8 (en) Molecules for disease detection and treatment
AU2002248723A8 (en) Molecules for disease detection and treatment
EP1390410A4 (en) Molecules for disease detection and treatment
GB2378440B (en) Acridine based molecules and processes for the preparation thereof
AU2002239543A1 (en) Molecules for disease detection and treatment
GB0130763D0 (en) Treatment methods
AU2003231245A8 (en) Molecules for disease detection and treatment
EP1390396A4 (en) Molecules for disease detection and treatment
GB0029524D0 (en) Disease treatment
AU2002320026A1 (en) Molecules for disease detection and treatment
AU5319400A (en) Molecules for disease detection and treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KABLE, AMY E.

Inventor name: LEE, SALLY

Inventor name: BARROSO, INES

Inventor name: KAMIGAKI, LAURA L.

Inventor name: STUVE, LAURA L.

Inventor name: AZIMZAI, YALDA

Inventor name: ZEBARJADIAN, YEGANEH

Inventor name: MASON, PATRICIA M.

Inventor name: RAMKUMAR, JAYALAXMI

Inventor name: PETERSON, DAVID P.

Inventor name: EMERLING, BROOKE M.

Inventor name: BOROWSKY, MARK L.

Inventor name: HONCHELL, CYNTHIA D.

Inventor name: DING, LI

Inventor name: HUANG, JIAQI

Inventor name: ISON, CRAIG H.

Inventor name: XU, YUMING

Inventor name: ARVIZU, CHANDRA S.

Inventor name: THANGAVELU, KAVITHA

Inventor name: CHAWLA, NARINDER K.

Inventor name: LU, DYUNG AINA M.

Inventor name: YUE, HUIBIN

Inventor name: LEE, ERNESTINE A.

Inventor name: KHAN, FARRAH, A.

Inventor name: RECIPON, SHIRLEY, A.

Inventor name: ELLIOTT, VICKI, S.

Inventor name: SWARNAKAR, ANITA

Inventor name: GRIFFIN, JENNIFER, A.

Inventor name: HAFALIA, APRIL, J.A.

Inventor name: TRAN, UYEN, K.

Inventor name: YANG, JUNMING

Inventor name: YAO, MONIQUE, G.

Inventor name: BECHA, SHANYA, D.

Inventor name: SANJANWALA, BHARATI

Inventor name: BURFORD, NEIL

Inventor name: RICHARDSON, THOMAS, W.

Inventor name: BANDMAN, OLGA

Inventor name: WARREN, BRIDGET, A.

Inventor name: DUGGAN, BRENDAN, M.

Inventor name: BAUGHN, MARIAH, R.

Inventor name: YUE, HENRY

Inventor name: TANG, TOM, Y.

Inventor name: LU, YAN

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/12 B

Ipc: 7C 07K 14/47 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051201